CV Satu Mustjoki 1

CURRICULUM VITAE 1. Personal details: • Mustjoki Satu Maarit, 08.01.1972 (date of birth), Finnish (nationality) • ORCID: 0000-0002-0816-8241, Website: www.helsinki.fi/hematology

2. Education and degrees completed: • Adjunct professor (docent), Experimental hematology, Univ. of Helsinki, 20.04.2011 • Specialist in Clinical Chemistry (Laboratory Hematology), Univ. of Helsinki, Finland, 28.08.2008 • PhD, University of Helsinki, Finland, PhD Thesis with honor, 27.02.2001 • MD, University of Helsinki, Finland, 30.09.1997

3. Current positions: • 1.9.2017- Professor of Translational Hematology (100%), Univ. of Helsinki, Finland. Mostly research position combined

with teaching • 1.4.2018- Head of department, HUH Comprehensive Cancer Center, Helsinki Finland. Leader of biomarker projects in

connection with clinical trials. 4. Previous work experience: • 2015-2017 Research professor for the Finnish Cancer Institute • 2015-2017 Deputy professor of Clinical Chemistry and Hematology (35% position), UH, Finland • 2012-2015 Specialist doctor (5% position), HUH Comprehensive Cancer Center, Helsinki Finland • 2010-2014 Senior Research fellow (Academy of Finland), HRUH, HUCH, Helsinki, Finland • 2008-2010 Academy Clinical Researcher, HRUH, HUCH, Helsinki, Finland, • 2007-2007 Resident in hematology, Dept. of Medicine, HUCH, Helsinki, Finland (4 months) • 2006-2006 Clinical lecturer, Dept. of Clinical Chemistry, University of Helsinki, Finland (6 months) • 2002-2006 Resident in Clinical Chemistry, Laboratory of Hematology, HUCH, Helsinki, Finland • 2001-2002 Post-Doctoral researcher, Molecular Cancer Biology (Group prof. K. Alitalo), UH (12 months) • 1995-2000 PhD student, Dept. of Virology (Cancer biology group prof. A. Vaheri), UH, Finland

5. Career breaks • Career breaks: 2 children born in 2002 and 2004; Clinical specialization 2002-2008

6. Personal research funding as PI (main grants during last 5 years listed) • European Research Council (ERC) consolidator grant 2015-2020, 2 047 000€; Academy of Finland Terva funding

2018-2020 373 617€, Finnish Cancer Organizations major grant 2017-2019, 450 000€; Academy of Finland 2015-2019, 458 215€; Sigrid Juselius Foundation 2017-2020, 75 000€/year; HiLife Fellow 2017-2020, 180 000€; Novartis investigator initiated grant 2017-2019, 400 000€; State funding for university level health research 2014-2017, 297 500€; Instrumentarium Science Foundation 2014-2015, 100 000€; Sigrid Juselius Foundation 2014-2016, 150 000€; Finnish Cancer Organizations, 2015-2016, 100 000€; Pfizer biomarker program, 2014-2017, 425 000€; Nordic Cancer Union, 2013-2015, 240 000€; Finnish Cancer Organizations, 2013-2014, 100 000€; Biocentrum Helsinki 2014-2016, 135 000€; Academy of Finland, 2013-2015, 284 168€; Sigrid Juselius Foundation 2010-2013, 144 000€; Academy of Finland (Academy Research fellow) 2010-2015, 391 510€

• Total competitive research funding as a PI during 2008-2018: 6 413 000€ and funding for academic biomarker trials from global pharma companies during 2009-2018: 1 923 000€

7. Leadership and Supervision experience • Supervisor in PhD thesis: PhD A. Kreutzman (2012, thesis with honor, “Antileukemic immune responses in CML”), PhD

S. Hernesniemi (2012, “ Aberrant kinase activation as a therapy target: CML as a model disease”), MD, PhD H. Rajala (2014, best thesis of the year, “ Molecular pathogenesis of LGL leukemia”), PhD M. Ilander (2016, “ T and NK cell mediated immunity in CML”), PhD E. Andersson (2017, “Characterization of mature T-cell leukemias by next-generation sequencing and drug sensitivity testing”), PhD P. Pietarinen (2017, “Effects of genotype and phenotype in personalized drug therapy”), MD, PhD M. El Missiry (2017, “Early Treatment Prediction and Immunological Effects of TKI Therapy in CML”), MD, PhD S. Söderlund (2017, “Clinical and Immunological studies in CML”). PhD H. Kuusanmäki (2018, “Targeting key survival signaling pathways in leukemia”). Currently ongoing 12 PhD thesis supervisions.

• Supervisor in MSc and MD thesis: MSc M. Ilander (2011), MSc E. Andersson (2012), MD K. Penttinen (2012), MSc S. Bortoluzzi (2015), MD E. Vakkila (2016), MD J. Eskelinen (2016), MSc H. Hakanen (2016), V. Gasparini 2016 (Univ. of Padua, Italy), M. Lee (2017), P. Savola (2018).

CV Satu Mustjoki 2

• Supervisor in Post-Doc studies: PhD Can Hekim (2012-2014), PhD Tiina Kelkka (2013-), PhD Giljun Park (2015-), PhD Anna Kreutzman (2015-), MD PhD Mikko Keränen (2015-), MD PhD Hanna Rajala (2016-), PhD Bhagwan Yadav (2017-), PhD Mette Ilander (2016-2017), PhD Khalid Saeed (2018-)

• Leader of research work: Program leader of Translational Immunology research program, University of Helsinki 2019-2024; Consortium PI Heal-Art Academy of Finland Terva project 2018-2020; Board member of Nordic CML study group 2010-

8. Teaching experience • Deputy prof. in Clinical Chemistry and Hematology responsible for undergraduate studies (medicine) and specialist

training in the Univ. of Helsinki, Finland, 1.3.2015- (Curriculum, planning of the tuition, lecturing, educational materials) • Board member in the Doctoral program in clinical research (Univ. of Helsinki) 2013-2017 and in the Doctoral program in

Biomedicine 2018- (Curriculum, educational administration) • Lecturer in courses associated to Helsinki Biomedical Graduate school and to Specialist training in Internal Medicine

and Clinical Chemistry 2010- (topics: Flow cytometry, scientific writing, laboratory hematology) • Invited lecturer in the educational sessions in the international conferences (2013-2016) • Doctor assistant and clinical lecturer, Department of Clinical Chemistry, University of Helsinki, Finland 1.8.2006-

31.1.2007 (Planning of courses, lecturing, seminars, devising exams) • Thesis committee member for 12 PhD students 2010-

9. Experience of organizing scientific meetings • Several Nordic CML study group scientific meetings and symposiums 2010-2018, Finnish Hematology association

meetings 2006-2010, Nordic Hematology meeting 2009. 100-300 participants. 10. Patents, inventions, awards and honors • Nomination for the Helsinki Institute of Life Science (HiLife) Fellow group for years 2017-2020 • ERC Consolidator grant awardee 2015 • Instrumentarium Science foundation fellow award (100 000€) 2014 • Senior research fellowship 2010-2015 and Clinical researcher fellowship 2008-2010 from the Academy of Finland • Nomination for the Biocentrum Helsinki research group for years 2014-2016 • One of the 7 research groups of the P-MOLMED (personalized molecular medicine) consortium which was ranked the

number 1 research network in the University of Helsinki evaluation in 2012 in the category of society impact • PhD thesis 2001 (Urokinase, Urokinase Receptor, and ICAMs in Human Leukemia) accepted with distinction • Several abstract awards (2008 XXII Olomouc Hematology Days, Olomouc, Czech Republic; 2008 13th Congress of the

European Hematology Association, Copenhagen, Denmark; 2009, 14th Congress of the European Hematology Association, Berlin, Germany; 2011, 16th Congress of the European Hematology Association, London, UK; 2012, 54th annual meeting of the American Society of Hematology, Outstanding Abstract Achievement Award, Atlanta, USA)

11. Other key academic merits • Vice director in the doctoral program of Clinical Investigation, University of Helsinki, Finland 2013-2017 • Vice director in the doctoral program of Biomedicine, University of Helsinki, Finland 2018- • Member of the Editorial Board: International Trends in Immunity (2013-), Cytokine (2014-) • Referee in international journals (hematology and immunology) and international peer evaluation of funding applications

(examples from 2017: Poland National Science Center funding program, Leuka JG Fellowship, ATIP-Avenir Fellowship program, ERC CoG application, UK Cancer research, Austria Science Foundation, Portugal Science funding)

• Abstract reviewer for the EHA and ASH conferences (2011, 2013, 2014, 2016, 2018) • Pre-examiner of a Doctoral dissertation 3 times (2014, 2015, 2016) • Principal investigator or study steering group member in international clinical studies run in European countries

(www.clinicaltrials.gov, NCT01725204, NCT00852566 and NCT01596114) 2009-; PI in 6 international biomarker discovery programs in association with clinical drug studies run in European countries 2009-; Sub-investigator in 24 international clinical trials in hematological malignancies using targeted drugs 2007-

• Only the main invited lectures in 2017-2018 are listed. Similar invited lectures regularly during previous years 2018: ESH CML conference, Miami; Japan Society of Hematology conference, Osaka; European LeukemiaNet (ELN) conference, Venice, Italy 2017: Immuno-Oncology Conference, Lisbon, Portugal; ELN conference, Mannheim, Germany, CML Scientific seminar, Sapporo, Okinawa and Tokyo, Japan; European Hematology Association Conference, Copenhagen, Denmark; Highlights of past EHA conference, Dubai, United Arab Emirates

12. Memberships and positions of trust in scientific societies • Member of the American Society of Hematology (ASH) scientific committee (myeloid neoplasia 2016-) • Board member of the Nordic CML study group 2010- and of the Finnish Soc. of Hematol. 2006-2010 • Memberships in professional societies: Finnish Medical Association, 1993-; Finnish Society of Hematology, 2002-; The

American Society of Hematology, 2008-; The European Society of Hematology, 2008-

CV Satu Mustjoki 3

13. Bibliometrics (Web of Science, 30.10.2018) • Total citations: 3435 Citations/article: 33 (Google scholar total citations 5593) • H-index: 27 (Google Scholar 33)

14. Total number of publications: • Altogether, 116 publications which consist of 100 original research journal articles, 12 review articles, 1 chapter in

research books, 2 editorials and 1 conference proceedings article all of which are published in peer-reviewed scientific journals.

10 SELECTED PUBLICATIONS RELATED TO APPLICATION

1. Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Adnan-Awad S, Eldfors S, Yadav B, Kuusanmaki H, Malani D, Andersson E, Pietarinen P, Saikko L, Kovanen P, Ojala T, Lee D, Loughran T, Nakazawa H, Suzumiya J, Suzuki R, Hyeh Ko Y, Seong Kim W, Chuang S, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. Mutational landscape of aggressive natural killer-cell leukemia and drug profiling highlight JAK-STAT signaling as a therapeutic target in NK-cell malignancies. Nat Commun. 2018;9:1567. (Characterization of mutational landscape and novel drug targets in NK-cell malignancies) IF 12.353, JR 3/64 Multidisciplinary Sciences, cited 2 times

2. Savola P, Bruck O, Olson T, Kelkka T, Kauppi MJ, Kovanen PE, Kytola S, Sokka-Isler T, Loughran TP, Leirisalo-Repo M, Mustjoki S. Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. Haematologica. 2018;103(2):304-312. IF 9.090, JR 5/71 Hematology

3. Ilander M, Olsson-Stromberg U, et al and Mustjoki S. Increased proportion of mature NK cells is associated with successful imatinib

discontinuation in chronic myeloid leukemia. Leukemia. 2017;31(5):1108-1116. (Discovery of immunological biomarker for successful therapy discontinuation in leukemia patients. Pan-European collaboration in clinical trial. PI of the study) IF 10.023, JR 4/71 Hematology, cited 32 times.

4. Savola P*, Kelkka T*, Rajala HL, Kuuliala A, Kuuliala K, Eldfors S, Ellonen P, Lagstrom S, Lepisto M, Hannunen T, Andersson EI, Khajuria RK, Jaatinen T, Koivuniemi R, Repo H, Saarela J, Porkka K*, Leirisalo-Repo M*, Mustjoki S*. *Equal contribution. Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. Nat Commun. 2017;8:15869. (Seminal discovery of clonal expansions carrying somatic mutations in patients with newly diagnosed rheumatoid arthritis) IF 12.353, JR 3/64 Multidisciplinary Sciences, cited 4 times

5. Coppe A, Andersson EI, Binatti A, Gasparini VR, Bortoluzzi S, Clemente M, Herling M, Maciejewski J, Mustjoki S*, Bortoluzzi S*. Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach. Leukemia. 2017;31(5):1243-1246.* Equal contribution. IF 10.023, JR 4/71 Hematology, cited 6 times.

6. Andersson E, Tanahashi T, et al and Mustjoki S*, Ishida F*. *equal senior authors. High incidence of activating STAT5B mutations in

CD4-positive T-cell large granular lymphocyte leukemia. Blood 2016 Nov 17;128(20):2465-2468. (Association of STAT5b mutations with CD4+ phenotype in LGL leukemia) IF 15.132, JR 2/71 Hematology, cited 13 times.

7. Flanagan, S.E., Haapaniemi, E., Russell, M.A., Caswell, R., Lango Allen, H., De Franco, E., McDonald, T.J., Rajala, H., Ramelius, A., Barton, J., Heiskanen, K., Heiskanen-Kosma, T., Kajosaari, M., Murphy, N.P., Milenkovic, T., Seppanen, M., Lernmark, A., Mustjoki, S., Otonkoski, T., Kere, J., Morgan, N.G., Ellard, S. & Hattersley, A.T. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nature Gen 2014, 46, 812-814. IF 27.125, JR 2/171 Genetics&Heredity, cited 142 times.

8. Clemente, M.J., Przychodzen, B., Jerez, A., Dienes, B.E., Afable, M.G., Husseinzadeh, H., Rajala, H.L., Wlodarski, M.W., Mustjoki, S. & Maciejewski, J.P. (2013) Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. Blood 2013, 122, 4077-4085. IF 15.132, JR 2/71 Hematology, cited 27 times.

9. Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S, Andersson EI, Jerez A, Clemente MJ, Yan Y, Zhang D, Awwad A, Ellonen P, Kallioniemi O, Wennerberg K, Porkka K, Maciejewski JP, Loughran TP, Jr., Heckman C, Mustjoki S. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013;121:4541-4550. (This was the first time to discover somatic mutations in STAT5 gene. Senior, corresponding author responsible for the whole study). IF 15.132, JR 2/71 Hematology, cited 103 times

10. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, Lagstrom S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepisto M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP, Jr., Heckman CA, Maciejewski JP, Mustjoki S. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366:1905-13. (Groundbreaking observation demonstrating that LGL leukemia is caused by activating STAT3 mutations. Corresponding author) IF 79.258, JR 1/155 Medicine, cited 306 times.

FULL PUBLICATION LIST

CV Satu Mustjoki 4

PART A

A. PEER-REVIEWED ORIGINAL SCIENTIFIC ARTICLES

1. Akenami F, Koskiniemi M, Mustjoki S, Siren V, Färkkilä M, Vaheri A. Plasma and cerebrospinal fluid activities of tissue plasminogen activator, urokinase and plasminogen activator inhibitor-1 in multiple sclerosis. Fibrinolysis & Proteolysis 1997;11:109-13.

2. Mustjoki S, Tapiovaara H, Siren V, Vaheri A. Interferons and retinoids enhance and dexamethasone suppresses urokinase-

mediated plasminogen activation in promyelocytic leukemia cells. Leukemia 1998;12:164-74. 3. Mustjoki S, Alitalo R, Stephens RW, Vaheri A. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia

patients: relationship to classification and response to therapy. Thromb Haemost 1999;81:705-10. 4. Mustjoki S, Sidenius N, Sier CF, Blasi F, Elonen E, Alitalo R, Vaheri A. Soluble urokinase receptor levels correlate with number

of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 2000;60:7126-32. 5. Mustjoki S, Sidenius N, Vaheri A. Enhanced release of soluble urokinase receptor by endothelial cells in contact with

peripheral blood cells. FEBS Lett 2000;486:237-42. 6. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA,

Achen MG, Alitalo K. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 2001;20:4762-73.

7. Mustjoki S, Alitalo R, Elonen E, Carpen O, Gahmberg CG, Vaheri A. Intercellular adhesion molecule-1 in extravasation of

normal mononuclear and leukaemia cells. Br J Haematol 2001;113:989-1000. 8. Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular

endothelial precursor cells. Blood 2003;101:168-72. 9. Mustjoki S, Lundan T, Knuutila S, Porkka K. Appearance of bone marrow lymphocytosis predicts an optimal response to

imatinib therapy in patients with chronic myeloid leukemia. Leukemia 2007;21:2363-8. 10. Borze I, Mustjoki S, Juvonen E, Knuutila S. Oligoarray comparative genomic hybridization in polycythemia vera and essential

thrombocythemia. Haematologica 2008;93:1098-100. 11. Lundan T, Juvonen V, Mueller MC, Mustjoki S, Lakkala T, Kairisto V, Hochhaus A, Knuutila S, Porkka K. Comparison of bone

marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia. Haematologica 2008;93:178-85.

12. Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L,

Hjorth-Hansen H, Hoglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005-12.

13. Mustjoki S, Borze I, Lasho TL, Alitalo R, Pardanani A, Knuutila S, Juvonen E. JAK2V617F mutation and spontaneous

megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV). Leuk Res 2009;33:54-9.

14. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Hoglund M, Kovanen P,

Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-405.

15. Mustjoki S, Hernesniemi S, Rauhala A, Kahkonen M, Almqvist A, Lundan T, Porkka K. A novel dasatinib-sensitive RCSD1-

ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica 2009;94:1469-71.

16. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S. Mono/oligoclonal T and NK

cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010;116:772-82.

CV Satu Mustjoki 5

17. Mustjoki S, Rohon P, Rapakko K, Jalkanen S, Koskenvesa P, Lundan T, Porkka K. Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy. Leukemia 2010;24:219-22.

18. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine

kinase inhibitor therapy. Eur J Haematol 2010;85:387-98. 19. Jalkanen SE, Vakkila J, Kreutzman A, Nieminen JK, Porkka K, Mustjoki S. Poor cytokine-induced phosphorylation in chronic

myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy. Exp Hematol 2011;39:102-13 e1.

20. *Kreutzman A*, Ladell K*, Koechel C, Gostick E, Ekblom M, Stenke L, Melo T, Einsele H, Porkka K, Price DA*, Mustjoki S*,

Seggewiss R* (*equal contribution). Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011;25:1587-97.

21. Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V, Voglova J, Sinisalo M, Flochova E, Vakkila J, Arstila P,

Porkka K, Mustjoki S. Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 2011;6:e23022.

22. Lahesmaa-Korpinen AM, Jalkanen S, Chen P, Valo E, Nunez-Fontarnau J, Rantanen V, Oghabian A, Vakkila J, Porkka K,

Mustjoki S, Hautaniemi S. FlowAnd: Comprehensive Computational Framework for Flow Cytometry Data Analysis. J Proteomics Bioinform 2011;4:245-9.

23. Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular

and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2011;52:668-79.

24. Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A, Bjoreman M, Flogegard M, Koskenvesa P,

Lindblom A, Malm C, Mustjoki S, Myhr-Eriksson K, Ohm L, Rasanen A, Sinisalo M, Sjalander A, Stromberg U, Bjerrum OW, Ehrencrona H, Gruber F, Kairisto V, Olsson K, Sandin F, Nagler A, Nielsen JL, Hjorth-Hansen H, Porkka K. Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011;118:3228-35.

25. De Braekeleer E, Douet-Guilbert N, Guardiola P, Rowe D, Mustjoki S, Zamecnikova A, Al Bahar S, Jaramillo G, Berthou C,

Bown N, Porkka K, Ochoa C, De Braekeleer M. Acute lymphoblastic leukemia associated with RCSD1-ABL1 novel fusion gene has a distinct gene expression profile from BCR-ABL1 fusion. Leukemia 2013 Jun;27(6):1422-4.

26. Jalkanen SE, Lahesmaa-Korpinen AM, Heckman CA, Rantanen V, Porkka K, Hautaniemi S, Mustjoki S. Phosphoprotein

profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients. Exp Hematol 2012;40:705-14 e3.

27. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, Lagstrom S, Clemente MJ, Olson T,

Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepisto M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP, Jr., Heckman CA, Maciejewski JP, Mustjoki S. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366:1905-13.

28. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, Olson T, Przychodzen B, Afable M, Gomez-Segui I,

Guinta K, Durkin L, Hsi ED, McGraw K, Zhang D, Wlodarski MW, Porkka K, Sekeres MA, List A, Mustjoki S, Loughran TP, Maciejewski JP. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012;120:3048-57.

29. Kreutzman A, Jaatinen T, Greco D, Vakkila E, Richter J, Ekblom M, Hjorth-Hansen H, Stenke L, Melo T, Paquette R,

Seggewiss-Bernhardt R, Guerci-Bresler A, Talbot A, Cayuela JM, Mahon FX, Porkka K, Lipton J, Partanen J, Rousselot P, Mustjoki S. Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Exp Hematol 2012;40:906-13 e1.

30. Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S,

Molimard M, Smykla R, Lee FY, Vakkila J, Jalkanen S, Salmi M, Porkka K. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 2013; Apr;27(4):914-24.

31. Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, Gjertsen BT, Hovland R, Hernesniemi S, Josefsen

D, Koskenvesa P, Dybedal I, Markevarn B, Olofsson T, Olsson-Stromberg U, Rapakko K, Thunberg S, Stenke L, Simonsson B, Porkka K, Hjorth-Hansen H. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia 2013;Jul;27(7):1520-6.

CV Satu Mustjoki 6

32. Christiansson L, Söderlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, Olsson-Stromberg U, Loskog A.

Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/ programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One 2013;8(1):e55818.

33. Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S, Andersson EI, Jerez A, Clemente MJ, Yan Y,

Zhang D, Awwad A, Ellonen P, Kallioniemi O, Wennerberg K, Porkka K, Maciejewski JP, Loughran TP, Jr., Heckman C, Mustjoki S. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013;121:4541-4550.

34. Mosakhani N, Mustjoki S, Knuutila S. Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia. Mol

Cytogenet. 2013 Jul 16;6(1):27. 35. Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Bespalov M, Ellonen P, Elonen E, Karjalainen R, Kulesskiy E, Lehto A,

Lundán T, Majumder M.M, Mattila P, Murumägi A, Mustjoki S, Parsons A, Pirttinen T, Rämet M.E, Turunen L, Knowles J, Aittokallio T, Heckman C, Porkka K, Kallioniemi O, Wennerberg K. Individualized Systems Medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013 Dec;3(12):1416-29.

36. Jerez A, Clemente MJ, Makishima H, Rajala H, Gomez-Segui I, Olson T, McGraw K, Przychodzen B, Kulasekararaj A, Afable

M, Husseinzadeh HD, Hosono N, LeBlanc F, Lagstrom S, Zhang D, Ellonen P, Tichelli A, Nissen C, Lichtin AE, Wodnar-Filipowicz A, Mufti GJ, List AF, Mustjoki S, Loughran TP, Jr., Maciejewski JP. STAT3-mutations indicate the presence of subclinical T cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013 Oct 3;122(14):2453-9.

37. Clemente, M.J., Przychodzen, B., Jerez, A., Dienes, B.E., Afable, M.G., Husseinzadeh, H., Rajala, H.L., Wlodarski, M.W.,

Mustjoki, S. & Maciejewski, J.P. (2013) Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. Blood 2013, 122, 4077-4085.

38. Andersson EI, Rajala HL, Eldfors S, Ellonen P, Olson T, Jerez A, Clement MJ, Kallioniemi O, Porkka K, Heckman C, Loughran

TP Jr, Maciejewski JP, Mustjoki S. Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. Blood Cancer J. 2013;3:e168.

39. Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, Räsänen A, Vapaatalo M, Remes K, Lundan T, Hjorth-Hansen

H, Vakkila J, Simonsson B, Mustjoki S*, Porkka K*. Imatinib and pegylated IFN-alpha2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. Eur J Haematol. 2014, 92: 413-420. *equal contribution.

40. Christiansson, L., Mustjoki, S., Simonsson, B., Olsson-Stromberg, U., Loskog, A. & Mangsbo, S.M. The use of Multiplex

Platforms for Absolute and Relative Protein Quantification of Clinical Material. EuPA Open Proteomics 2014. In press. 41. Kontro, M., Kuusanmaki, H., Eldfors, S., Burmeister, T., Andersson, E.I., Bruserud, O., Brummendorf, T.H., Edgren, H.,

Gjertsen, B.T., Itala-Remes, M., Lagsrtom, S., Lohi, O., Lundan, T., Marti, J.M., Majumder, M.M., Parsons, A., Pemovska, T., Rajala, H., Vettenranta, K., Kallioniemi, O., Mustjoki, S., Porkka, K. & Heckman, C.A. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia 2014 Aug;28(8):1738-42.

42. Pirnes-Karhu, S., Jantunen, E., Mäntymaa, P., Mustjoki, S., Alhonen, L. & Uimari, A. Spermidine/spermine N1-

acetyltransferase activity associates with white blood cell count in myeloid leukemias. Exp Hematol 2014 Jul;42(7):574-80. 43. Andersson, E., Eldfors, S., Edgren, H., Ellonen, P., Vakeva, L., Ranki, A. & Mustjoki, S. Novel TBL1XR1, EPHA7 and SLFN12

mutations in a Sezary syndrome patient discovered by whole exome sequencing. Exp Dermatol 23, 366-368, 2014. 44. Hjorth-Hansen, H., Stenke, L., Soderlund, S., Dreimane, A., Ehrencrona, H., Gedde-Dahl, T., Gjertsen, B.T., Hoglund, M.,

Koskenvesa, P., Lotfi, K., Majeed, W., Markevarn, B., Ohm, L., Olsson-Stromberg, U., Remes, K., Suominen, M., Simonsson, B., Porkka, K., Mustjoki, S., Richter, J. The Nordic, C.M.L.S.G. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase: Clinical results from a randomized phase 2 study (NordCML006). Eur J Haematol 94, 243-250, 2015.

45. Ilander M, Koskenvesa P, Hernesniemi S, Lion T, Porkka K and Mustjoki S. Induction of sustained deep molecular response in

a chronic-phase T315I- mutated chronic myeloid leukemia patient with interferon-alfa monotherapy. Leuk Lymph. 2014 Apr;55(4):934-7.

46. Seppänen M, Koillinen H, Mustjoki S, Mälkönen T, Sullivan KE. Terminal Deletion of 11q with Significant Late-Onset Combined

Immune Deficiency. J Clin Immunol. 2014 Apr;55(4):934-7 47. Ilander, M., Kreutzman, A., Rohon, P., Melo, T., Faber, E., Porkka, K., Vakkila, J. & Mustjoki, S. Enlarged Memory T-Cell Pool

and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-alpha

CV Satu Mustjoki 7

Monotherapy. PLoS One 2014, 9, e87794. IF 3.730 (Functional analysis of immune effector cells in CML patients who have been cured)

48. Kreutzman, A., Ilander, M., Porkka, K., Vakkila, J. & Mustjoki, S. Dasatinib promotes Th1-type responses in granzyme B

expressing T-cells. Oncoimmunology 2014, 3, e28925. 49. Flanagan, S.E., Haapaniemi, E., Russell, M.A., Caswell, R., Lango Allen, H., De Franco, E., McDonald, T.J., Rajala, H.,

Ramelius, A., Barton, J., Heiskanen, K., Heiskanen-Kosma, T., Kajosaari, M., Murphy, N.P., Milenkovic, T., Seppanen, M., Lernmark, A., Mustjoki, S., Otonkoski, T., Kere, J., Morgan, N.G., Ellard, S. & Hattersley, A.T. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nature Gen 2014, 46, 812-814.

50. Loughran, T.P., Jr., Zickl, L., Olson, T.L., Wang, V., Zhang, D., Rajala, H.L., Hasanali, Z., Bennett, J.M., Lazarus, H.M., Litzow,

M.R., Evens, A.M., Mustjoki, S. & Tallman, M.S. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 2015 Apr;29(4):886-94.

51. Christiansson, L., Soderlund, S., Mangsbo, S.M., Hjorth-Hansen, H., Hoglund, M., Markevarn, B., Richter, J., Stenke, L.,

Mustjoki, S., Loskog, A. & Olsson-Stromberg, U. The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses. Mol Cancer Ther. 2015 May;14(5):1181-91.

52. Haapaniemi, E.M., Kaustio, M., Rajala, H.L., van Adrichem, A.J., Kainulainen, L., Glumoff, V., Doffinger, R., Kuusanmaki, H.,

Heiskanen-Kosma, T., Trotta, L., Chiang, S., Kulmala, P., Eldfors, S., Katainen, R., Siitonen, S., Karjalainen-Lindsberg, M.L., Kovanen, P.E., Otonkoski, T., Porkka, K., Heiskanen, K., Hanninen, A., Bryceson, Y.T., Uusitalo-Seppala, R., Saarela, J.*, Seppanen, M.*, Mustjoki, S.* & Kere, J. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood 125, 639-648, 2015. * Corresponding author

53. Rajala, H.L., Olson, T., Clemente, M.J., Lagstrom, S., Ellonen, P., Lundan, T., Hamm, D.E., Zaman, S.A., Lopez Marti, J.M.,

Andersson, E.I., Jerez, A., Porkka, K., Maciejewski, J.P., Loughran, T.P. & Mustjoki, S. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. Haematologica 100, 91-99, 2015.

54. Pietarinen, P., Pemovska, T., Kontro, M., Bhagwan, Y., Mpindi, J.P., Andersson, E., Majumder, M.M., Kuusanmaki, H.,

Koskenvesa, P., Kallioniemi, O., Wennerberg, K., Heckman, C., Mustjoki, S.* & Porkka, K.*Equal senior authors. Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. Blood Cancer J 2015 May 1;5:e309.

55. Andersson E, Kuusanmäki H, Bortoluzzi S, Lagström S, Parsons A, Rajala H, van Adrichem A, Eldfors S, Olson T, Clemente

MJ, Laasonen A, Ellonen P, Heckman C, Loughran TP, Maciejewski JP, Mustjoki S. Activating somatic mutations outside the SH2-domain of STAT3 in LGL Leukemia. Leukemia. 2016 May;30(5):1204-8.

56. Landberg, N., Hansen, N., Askmyr, M., Agerstam, H., Lassen, C., Rissler, M., Hjorth-Hansen, H., Mustjoki, S., Jaras, M.,

Richter, J. & Fioretos, T. IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome. Leukemia 2016 Jan;30(1):253-7.

57. El Missiry, M., Adnan Awad, S., Rajala, H.L., Al-Samadi, A., Ekblom, M., Markevan, B., Astrand-Grundstrom, I., Wold, M.,

Svedahl, E.R., Juhl, B.R., Bjerrum, O.W., Haulin, I., Porkka, K., Olsson-Stromberg, U., Hjorth-Hansen, H. & Mustjoki, S. Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia. J Cancer Res Clin Oncol 2016;142(5):1041-50.

58. Hannula-Jouppi, K., Laasanen, S.L., Ilander, M., Furio, L., Tuomiranta, M., Marttila, R., Jeskanen, L., Hayry, V., Kanerva, M.,

Kivirikko, S., Tuomi, M.L., Heikkila, H., Mustjoki, S., Hovnanian, A. & Ranki, A. Intrafamily and Interfamilial Phenotype Variation and Immature Immunity in Patients With Netherton Syndrome and Finnish SPINK5 Founder Mutation. JAMA Dermatol. 2016 Apr 1;152(4):435-42.

59. Thielen, N., Richter, J., Baldauf, M., Barbany, G., Fioretos, T., Giles, F., Gjertsen, B.T., Hochhaus, A., Jan Schuurhuis, G.,

Sopper, S., Stenke, L., Thunberg, S., Wolf, D., Ossenkoppele, G., Porkka, K., Janssen, J. & Mustjoki, S. Leukemic stem cell quantification in newly diagnosed chronic myeloid leukemia patients predicts response to nilotinib therapy. Clin Cancer Res 2016 Mar 22.

60. Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, Höglund M, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Gruber

FX, Stenke L, Eriksson KM, Markevärn B, Lübking A, Vestergaard H, Udby L, Bjerrum OW, Persson I, Mustjoki S*, Olsson-Strömberg U*. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 2016 Jun 3. *shared last authors

CV Satu Mustjoki 8

61. Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NP. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. 2016 May 1;122(9):1398-407.

62. Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F,

Hochhaus A, Ernst T, Schenk T, Janssen J, Ossenkoppele G, Porkka K, Wolf D. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor (TKI) therapy in early Chronic Phase Chronic Myelogenous Leukemia (CML-CP). J Clin Oncol. 2016. 2017 Jan 10;35(2):175-184.

63. Ågerstam H, Hansen N, Von Palffy S, Reckzeh K, Karlsson C, Liljebjörn H, Landberg N, Askmyr M, Sanden C, Högberg C,

Rissler M, Porkka K, Wadenvik H, Mustjoki S, Richter J, Järas M, Fioretos T. IL1RAP antibodies block IL1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood 2016 Dec 8;128(23):2683-2693

64. Haapaniemi E, Fogarty C, Keskitalo S, Katayama S, Vihinen H, Ilander M, Krutskov K, Mustjoki S, Lehto M, Hautala T,

Eriksson O, Jokitalo E, Velagapudi V, Varjosalo M, Seppanen M, Kere, J. Combined immunodeficiency with hypoglycemia caused by mutations in hypoxia up-regulated 1. J Allergy Clin Immunol 2016 Nov 29

65. Söderlund S, Christiansson L, Persson I, Mustjoki S, Olsson-Stromberg U, Loskog A. Title Plasma Proteomics in CML Patients

Before and After Initiation of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity and Loss of Angiogenic Stimuli. Leukemia Res 2016 Nov;50:95-103.

66. Andersson E, Tanahashi T, Sekiguchi N, Gasparini V, Bortoluzzi S, Matsuda K, Mitsui T, Eldfors S, Bortoluzzi S, Coppe A,

Binatti A, Lagsrtom S, Ellonen P, Fukushima N, Nishina S, Senoo N, Sakai H, Nakazawa H, Kwong Y-L, Loughran TP, Maciejewski JP, Mustjoki S*, Ishida F*. *equal senior authors. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood 2016 Nov 17;128(20):2465-2468.

67. Ilander M, Olsson-Stromberg U, Schlums H, Guilhot J, Bruck O, Lahteenmaki H, Kasanen T, Koskenvesa P, Soderlund S,

Hoglund M, Markevarn B, Sjalander A, Lotfi K, Dreimane A, Lubking A, Holm E, Bjoreman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31(5):1108-1116.

68. Kaustio M, Haapaniemi E, Göös H, Hautala T, Park G, Syrjänen J, Einarsdottir E, Sahu B, Kilpinen S, Rounioja S, Fogarty C,

Glumoff V, Kulmala P, Katayama S, Tamene F, Trotta L, Morgunova E, Krutskov K, Nurmi K, Eklund K, Lagerstedt A, Helminen M, Martelius T, Mustjoki S, Taipale J, Saarela J, Kere J, Varjosalo M, Seppänen M. Damaging heterozygous mutations in NFKB1 lead to diverse immunological phenotypes. J Allergy Clin Immunol. 2017 Jan 20.

69. Heikkinen T, Kämpjärvi K, Keskitalo S, Von Nandelstadh P, Liu X, Rantanen V, Pitkänen E, Kinnunen M, Kuusanmaki H, Kontro

M, Turunen M, Mäkinen N, Taipale J, Heckman C, Lehti K, Mustjoki S, Varjosalo M, Vahteristo P. Somatic MED12 nonsense mutation escapes mRNA decay and reveals a motif required for nuclear entry. Hum Mutat. 2017 Mar;38(3):269-274.

70. Valori M, Jansson L, Kiviharju A, Ellonen P, Rajala H, Adnan Awad S, Mustjoki S, Tienari P. A novel class of somatic

mutations in blood detected preferentially in CD8+ cells. Clin Immunol. 2017 Feb;175:75-81. 71. El Missiry M, Hjorth-Hansen H, Richter J, Olson-Stromberg U, Stenke L, Porkka K, Kreutzman A and Mustjoki S. Early BCR-

ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. PLoS One. 2017;12(1):e0171041.

72. Warfvinge R, Geironson Ulfsson L, Sommarin MN, Lang S, Karlsson C, Roschupkina T, Stenke L, Stentoft J, Olsson-Stromberg

U, Hjorth-Hansen H, Mustjoki S, Soneji S, Richter J and Karlsson G. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood. 2017;129(17):2384-2394.

73. Hekim C, Ilander M, Yan J, Michaud E, Smykla R, Vähä-Koskela M, Savola P, Tähtinen S, Saikko L, Hemminki A, Kovanen PE,

Porkka K, Lee FY, Mustjoki S. Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. Cancer Immunol Res. 2017 Feb;5(2):157-169.

74. Coppe A, Andersson EI, Binatti A, Gasparini VR, Bortoluzzi S, Clemente M, Herling M, Maciejewski J, Mustjoki S*, Bortoluzzi

S*. Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach. Leukemia. 2017;31(5):1243-1246.* Equal contribution.

75. Schubert C, Chatain N, Braunschweig T, Schemionek M, Feldberg K, Hoffmann M, Dufva O, Mustjoki S, Brummendorf TH,

Koschmieder S. The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients. Oncotarget. 2017;8(21):34736-34749.

CV Satu Mustjoki 9

76. Rajala HLM, Missiry ME, Ruusila A, Koskenvesa P, Brummendorf TH, Gjertsen BT, Janssen J, Lotfi K, Markevarn B, Olsson-Stromberg U, Stenke L, Stentoft J, Richter J, Hjorth-Hansen H, Kreutzman A, Mustjoki S. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2017;143(8):1543-1554.

77. Pietarinen PO, Eide CA, Ayuda-Duran P, Potdar S, Kuusanmaki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman

CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S*, Porkka K*. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget. 2017;8(14):22606-22615.* Equal contribution.

78. Kaartinen T, Luostarinen A, Maliniemi P, Keto J, Arvas M, Belt H, Koponen J, Makinen PI, Loskog A, Mustjoki S, Porkka K,

Yla-Herttuala S, Korhonen M. Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion. Cytotherapy. 2017.

79. Dolinska M, Piccini A, Wong WM, Gelali E, Johansson AS, Klang J, Xiao P, Yektaei-Karin E, Stromberg UO, Mustjoki S,

Stenke L, Ekblom M, Qian H. Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38- stem and progenitor cells in chronic myeloid leukemia. Biochem Biophys Res Commun. 2017;490(2):378-384.

80. Gullaksen SE, Skavland J, Gavasso S, Tosevski V, Warzocha K, Dumrese C, Ferrant A, Gedde-Dahl T, Hellmann A, Janssen

J, Labar B, Lang A, Majeed W, Mihaylov G, Stentoft J, Stenke L, Thaler J, Thielen N, Verhoef G, Voglova J, Ossenkoppele G, Hochhaus A, Hjorth-Hansen H, Mustjoki S, Sopper S, Giles F, Porkka K, Wolf D, Gjertsen BT. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 2017;102(8):1361-1367.

81. Giustacchini A, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, Sopp P, Norfo R, Rodriguez-Meira A, Ashley N,

Jamieson L, Vyas P, Anderson K, Segerstolpe A, Qian H, Olsson-Stromberg U, Mustjoki S, Sandberg R, Jacobsen SEW, Mead AJ. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med. 2017;23(6):692-702.

82. Savola P, Kelkka T, Rajala HL, Kuuliala A, Kuuliala K, Eldfors S, Ellonen P, Lagstrom S, Lepisto M, Hannunen T, Andersson EI,

Khajuria RK, Jaatinen T, Koivuniemi R, Repo H, Saarela J, Porkka K, Leirisalo-Repo M, Mustjoki S. Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. Nat Commun. 2017;8:15869.

83. Andersson EI, Putzer S, Yadav B, Dufva O, Khan S, He L, Sellner L, Schrader A, Crispatzu G, Oles M, Zhang H, Adnan S,

Lagstrom S, Bellanger D, Mpindi JP, Eldfors S, Pemovska T, Pietarinen P, Lauhio A, Tomska K, Cuesta-Mateos C, Faber E, Koschmieder S, Brummendorf TH, Kytola S, Savolainen ER, Siitonen T, Ellonen P, Kallioniemi O, Wennerberg K, Ding W, Stern MH, Huber W, Anders S, Tang J, Aittokallio T, Zenz T, Herling M, Mustjoki S. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia. 2018;32(3):774-787.

84. Sopper S, Mustjoki S, Gjertsen BT, Giles F, Hochhaus A, Janssen J, Porkka K, Wolf D. NK cell dynamics and association with

molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. Leukemia. 2017;31(10):2264-2267.

85. Kreutzman A, Colom-Fernandez B, Marcos Jimenez A, Ilander M, Cuesta-Mateos C, Perez-Garcia Y, Delgado Arevalo C,

Bruck O, Hakanen H, Saarela J, Ortega-Carrion A, de Rosendo A, Juanes-Garcia A, Steegmann JL, Mustjoki S, Vicente-Manzanares M, Munoz-Calleja C. Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner. Clin Cancer Res. 2017;23(21):6697-6707.

86. Kuusanmaki H, Dufva O, Parri E, van Adrichem AJ, Rajala H, Majumder MM, Yadav B, Parsons A, Chan WC, Wennerberg K,

Mustjoki S*, Heckman CA*. Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget 2017;8(57):97516-97527.*equal contribution.

87. Dietrich S, Oles M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hullein J, da Silva Liberio M, Walther T, Wagner L, Rabe S,

Ghidelli-Disse S, Bantscheff M, Oles AK, Slabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Durig J, Ringshausen I, Zapatka M, Huber W, Zenz T. Drug-perturbation-based stratification of blood cancer. J Clin Invest. 2018;128(1):427-445.

88. He L, Tang J, Andersson EI, Timonen S, Koschmieder S, Wennerberg K, Mustjoki S, Aittokallio T. Patient-customized Drug

Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. Cancer Res. 78, 2407-2418, 2018.

CV Satu Mustjoki 10

89. Landberg N, von Palffy S, Askmyr M, Lilljebjorn H, Sanden C, Rissler M, Mustjoki S, Hjorth-Hansen H, Richter J, Agerstam H, Jaras M, Fioretos T. CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting. Haematologica. 2018;103(3):447-455.

90. Lissina A, McLaren JE, Ilander M, Andersson EI, Lewis CS, Clement M, Herman A, Ladell K, Llewellyn-Lacey S, Miners KL,

Gostick E, Melenhorst JJ, Barrett AJ, Price DA*, Mustjoki S*, Wooldridge L*. *shared. Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8(+) TCR-Vbeta(+) expansions. Sci Rep. 2018;8(1):2534.

91. Savola P, Bruck O, Olson T, Kelkka T, Kauppi MJ, Kovanen PE, Kytola S, Sokka-Isler T, Loughran TP, Leirisalo-Repo M,

Mustjoki S. Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. Haematologica. 2018;103(2):304-312.

92. Schneider-Hohendorf T, Gorlich D, Savola P, Kelkka T, Mustjoki S, Gross CC, Owens GC, Klotz L, Dornmair K, Wiendl H,

Schwab N. Sex bias in MHC I-associated shaping of the adaptive immune system. Proc Natl Acad Sci U S A. 2018;115(9):2168-2173.

93. Schrader A, Crispatzu G, Oberbeck S, Mayer P, Putzer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T,

Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmuller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brummendorf TH, Nurnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018;9(1):697.

94. Trotta L, Martelius T, Siitonen T, Hautala T, Hamalainen S, Juntti H, Taskinen M, Ilander M, Andersson EI, Zavialov A, Kaustio

M, Keski-Filppula R, Hershfield M, Mustjoki S*, Tapiainen T*, Seppanen M*, Saarela J*. *shared. ADA2 deficiency: Clonal lymphoproliferation in a subset of patients. J Allergy Clin Immunol. 2018;141(4):1534-1537 e1538.

95. Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Adnan-Awad S, Eldfors S, Yadav B, Kuusanmaki H, Malani D, Andersson E,

Pietarinen P, Saikko L, Kovanen P, Ojala T, Lee D, Loughran T, Nakazawa H, Suzumiya J, Suzuki R, Hyeh Ko Y, Seong Kim W, Chuang S, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. Mutational landscape of aggressive natural killer-cell leukemia and drug profiling highlight JAK-STAT signaling as a therapeutic target in NK-cell malignancies. Nat Commun. 2018;9:1567.

96. Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen J, Mayer J, Koskenvesa P, Panayiotidis P,

Olsson-Stromberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machova Polakova K, Muller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX, investigators E-S. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 19, 747-757, 2018.

97. Bouillon AS, Ventura Ferreira MS, Awad SA, Richter J, Hochhaus A, Kunzmann V, Dengler J, Janssen J, Ossenkoppele G,

Westerweel PE, Te Boekhorst PAW, Mahon FX, Hjorth-Hansen H, Isfort S, Fioretos T, Hummel S, Schemionek M, Wilop S, Koschmieder S, Saussele S, Mustjoki S, Beier F, Brummendorf TH. Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia. Blood Adv 2, 1572-1579, 2018.

98. Pollari M, Bruck O, Pellinen T, Vahamurto P, Karjalainen-Lindsberg ML, Mannisto S, Kallioniemi O, Kellokumpu-Lehtinen PL,

Mustjoki S, Leivonen SK, Leppa S. PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma. Haematologica 2018.

99. Bruck O, Blom S, Dufva O, Turkki R, Chheda H, Ribeiro A, Kovanen P, Aittokallio T, Koskenvesa P, Kallioniemi O, Porkka K,

Pellinen T, Mustjoki S. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia 2018.

100. Savola P, Lundgren S, Keranen MAI, Almusa H, Ellonen P, Leirisalo-Repo M, Kelkka T, Mustjoki S. Clonal hematopoiesis in

patients with rheumatoid arthritis. Blood Cancer J 8, 69, 2018. ORIGINAL PEER-REVIEWED ARTICLES IN SCIENTIFIC EDITED BOOKS OR PRINTED CONGRESS PUBLICATIONS 1. Mustjoki S, Jansson SE, Alitalo R, Alitalo K. Vascular endothelial growth factors and their receptors in endothelial and

haemapoietic precursor cells and in haematopoietic malignancies. EHA Educational Book 2001:210-5. PEER-REVIEWED REVIEWS AND EDITORIALS IN INTERNATIONAL SCIENTIFIC PUBLICATION SERIES AND TEXTBOOKS.

CV Satu Mustjoki 11

1. Mustjoki S, Alitalo R, Stephens RW, Vaheri A. Plasminogen activation in human leukemia and in normal hematopoietic cells.

APMIS 1999;107:144-9. 2. Mustjoki S, Alitalo R, Vaheri A. Role of plasminogen activation in hematopoietic malignancies and in normal hematopoiesis.

Plasminogen: Structure, Activation and Regulation: Kluwer Academic Publishers, USA; 2002. 3. Gruber F, Mustjoki S, Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive

acute lymphoblastic leukaemia. Br J Haematol 2009;145:581-97. 4. Porkka K, Mustjoki S, Simonsson B. Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms. Expert

Rev Hematol 2009;2:81-91. 5. Knuutila S, Mustjoki S. Morphology antibody chromosome technique for determining phenotype and genetic status of the same

cell. Curr Protoc Hum Genet 2012;Chapter 4:Unit4 7. 6. Kreutzman, K. Porkka and S. Mustjoki. Immunomodulatory Effects of Tyrosine Kinase Inhibitors. ITI 2013; 1(3): 22-33. 7. Rajala H and Mustjoki S. STAT5b in the pathogenesis of LGL leukemia – a novel therapeutic target? Oncotarget. 2013

Jun;4(6):808-9. 8. Ilander M, Hekim C, Mustjoki S. Immunology and immunotherapy of chronic myeloid leukemia. Curr Hematol Malig Rep.

2014, 9, 17-23. 9. Rajala H, Porkka K, Maciejewski J, Loughran T, Mustjoki S. Uncovering the pathogenesis of large granular lymphocytic

leukemia – novel STAT3 and STAT5b mutations. Ann Med. 2014 May;46(3):114-22. 10. Ilander, M., Kreutzman, A., Mustjoki, S. IFNalpha induces prolonged remissions modeling curative immunologic responses in

chronic myeloid leukemia. Oncoimmunology 2014, 3, e28781. 11. Ilander M, Mustjoki S. Immune control in chronic myeloid leukemia. Oncotarget. 2017;8(61):102763-102764. 12. Mustjoki S. Non-Ph variants in CML: guilty drivers? Blood 132, 880-881, 2018.

ORIGINAL ARTICLES AND REVIEWS IN FINNISH TEXTBOOKS AND PUBLICATION SERIES WITH A PEER REVIEW SYSTEM 1. Mustjoki S. Leukemian alkulähteillä. [Finnish. In the origin of leukemia]. KliinLab 2009;4:80-4. 2. Koskela H, Koskenvesa P, Mustjoki S, Porkka K. Kroonisen myelooisen leukemia nykyhoito. [Finnish. Current therapy of

chronic myeloid leukemia]. Duodecim 2012;128:579-88. 3. Savola, P., Rajala, H., Mustjoki, S. LGL-leukemia ja autoimmuniteetti - autoimmuunisairauden ja syövän rajapinta hämärtyy.

[Finnish. LGL leukemia and autoimmunity: on the borderline between malignant and benign disorder]. Duodecim 2016; 132(15):1328-35.

4. Bruck, O., Keränen, M., Dufva, O., Kreutzman, A., Mustjoki, S. T-solut ja syöpä - miksi tappajat uupuvat? [Finnish. T cells

and cancer-why killer cells get exhausted?]. Duodecim 132, 1984-1992, 2016.

D. PUBLICATIONS INTENDED FOR PROFESSIONAL COMMUNITIES

1. Mustjoki S. Leukemian alkulähteillä. (Finnish. In the origin of leukemia). KliinLab 2009;4:80-4. 2. Mustjoki S. Uutta tietoa KML:sta ja sisarustaudeista. (Finnish. Novel data from CML and related diseases). ASH report 2012.

(A publication in Finnish for medical doctors. An update of current research progress in hematology). 3. Mustjoki S, Porkka K. CML Immunology: an update. 10th Information Letter of the European LeukemiaNet (ELN), WP4. 2014 4. Mustjoki S, Petterson T, Sinisalo M, Vakkila J. Veritautien immunologiaa (Immunology in hematological disorders). Book

chapter in: Veritaudit (publisher Duodecim 2014 edition.

CV Satu Mustjoki 12

5. Mustjoki S, Koistinen P. Krooninen myeloinen leukemia (Chronic myeloid leukemia). Book chapter in Veritaudit (publisher

Duodecim 2014 edition) 6.

E. PUBLICATIONS INTENDED FOR THE GENERAL PUBLIC, LINKED TO THE APPLICANT’S RESEARCH 1. Mustjoki S. Leukemia-no longer a death sentence. Pan European Networks: Science &Technology. 2013:08 2. Mustjoki S. An end to leukaemia? Horizon2020 projects, 2014:2. 3. Mustjoki S. Superior treatment responses; novel treatment options in leukemia. Pan European Networks: Science &

Technology. 2014: 12

G. THESIS DOCTORAL DISSERTATION 1. Mustjoki S. Urokinase, Urokinase Receptor, and ICAMs in Human Leukemia. Helsinki University Biomedical dissertations

No. 4, University of Helsinki, Finland 2001. H. PATENTS AND INNOVATION DISCLOSURES 1. Diagnostic anti-COX-2 autoantibody for acquired bone marrow failure. Tiina Kelkka, Mikko Tyster, Sofie Lundgren, Mikko Keränen, Satu Mustjoki. University of Helsinki. 760/2018 I. AUDIOVISUAL MATERIAL, ICT SOFTWARE 1. Mustjoki S, Koskenvesa P, Porkka K, Kairisto V, Koskela H. www.hematology.fi/cml. National treatment guidelines and

educational material in Finnish for hematologists about chronic myeloid leukemia. 2. Koskenvesa P, Mustjoki S, Rosenberg-Ryhänen L. http://www.syopapotilaat.fi/potilasoppaat/kml-potilaan-opas/. Educational

material in Finnish for patients with chronic myeloid leukemia and their relatives.